BCAX
Bicara Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Ficerafusp Alfa plus pembrolizumab shows strong three-year survival and deep responses in head and neck cancer studyMay 23, 2026
- Ficerafusp Alfa 2000mg Q2W delivered deep and durable responses in first-line recurrent/metastatic HPV-negative HNSCC, supporting less frequent dosing developmentFeb 20, 2026
- Bicara Therapeutics announces Ficerafusp Alfa granted breakthrough therapy designation by U.S. FDA for first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinomaOct 13, 2025